Gsk Share Discussion Threads

[johnrxx99] 27/6/2022 05:25

"...to provide consistency in the GSK share price pre- and post-separation (subject to interim market movements), in order to enable comparability between the Company's earnings per share and share price with previous periods."


Doesn't share consolidation mean a reduction/split in the number of shares? It does not say the same number of shares and you cannot provide consistency in pre- and post separation without changing something. Consistency to compare eps and share price with previous periods.

So if you want a post position to be consistent to the previous year/period, the number of shares you divide into the new earnings must be less than the ones you divided last years earnings by. You cannot magic value out of finite resources, only the demand for those resources will increase value.

[jonjoneil] 26/6/2022 15:52

You are right. GARYCOOK has got it wrong

[zho] 26/6/2022 14:56

>>Looking like maybe around £10 for New GSK>>

I don't get that. Glaxo are consolidating GSK shares for reasons of "consistency" - so that the share price after the split looks pretty much as it did before the split. Or at least, that's how I understand this paragraph:

"Following completion of the Demerger and listing of Haleon, GSK intends to carry out the GSK Share Consolidation. This is intended to provide consistency in the GSK share price pre- and post-separation (subject to interim market movements), in order to enable comparability between the Company's earnings per share and share price with previous periods."

[garycook] 26/6/2022 14:37

TM,Just rough calculations to see the reaction,s on the subject ? But seeing GSK shareholders will be retaining the same number of shares,and issued with the same number of Haleon shares,then the share price will be adjusted accordingly.

[jonjoneil] 26/6/2022 12:28

Provided recession hasn't bombed out the market, I think New GSK could open around £19.(or get there within a few days of opening).
Remember we will each be holding significantly less of them.

Just my thoughts when looking up at AZN.

[tradermichael] 26/6/2022 09:26

Where did that come from? Does that suggest no premium from Friday's closing price?

[garycook] 26/6/2022 08:41

Looking like maybe around £10 for New GSK,and 750p for Haleon atm

[grupo guitarlumber] 26/6/2022 07:28

Drugs giant GSK says encouraging results from trial of its hepatitis B treatment raises hopes for millions suffering from chronic infection

By Neil Craven, Financial Mail on Sunday

Published: 21:50 BST, 25 June 2022 | Updated: 23:17 BST, 25 June 2022


Drugs giant GSK said encouraging results from a trial of its hepatitis B treatment have raised hopes for millions suffering from chronic infection.

It estimated its treatment bepirovirsen could generate peak annual sales of more than £2billion ($2.5billion) if later stage trials are successful.
Boost: GSK estimated its treatment bepirovirsen could generate peak annual sales of more than £2billion ($2.5billion) if later stage trials are successful

Boost: GSK estimated its treatment bepirovirsen could generate peak annual sales of more than £2billion ($2.5billion) if later stage trials are successful

The development follows positive news earlier this month from a phase three trial in older adults for its RSV vaccine for respiratory disease.

Shareholders including activist Elliott view the RSV vaccine, for which GSK will seek approval by the end of the year, as vital for the company's success and are likely to be cheered by the encouraging data on bepirovirsen.


How to choose the best (and cheapest) stocks and shares Isa and the right DIY investing platform

There are already effective vaccines for hepatitis B. But nearly 300 million people suffer long-lasting complications when the body is unable to fend off the virus.

Around 900,000 patients die each year from chronic hepatitis B and, even when treated, it can progress to complications including cirrhosis and liver cancer.

The pharmaceutical company said initial results from a mid-stage study raised hopes for what it called a 'functional cure'.

Chris Corsico, a senior vice president at the company, said yesterday the treatment has the potential to be 'transformative.'

GSK, whose chief executive Dame Emma Walmsley has been under attack by Elliott and other shareholders, is poised to spin off its Sensodyne toothpaste and Advil painkillers consumer healthcare business, Haleon, next month.

[jonjoneil] 25/6/2022 17:37

Unless they set a lowish price for Haleon at opening, I don't expect it to hold. Whereas I expect new GSK to open at a premium.

Question is, will the balance be positive?

[tradermichael] 25/6/2022 12:49

Destiny for Haleon ........?

[tradermichael] 25/6/2022 12:22

Well, one of the few multivalent boosters, I think - could be key to seeing off these newer Omicron strains and therefore an important milestone?

[patientcapital] 25/6/2022 09:47

Better late than never!

[tradermichael] 25/6/2022 08:14

I suppose this will be on the menu for the autumn vaccinations:

Sanofi SA said Friday that its coronavirus booster vaccine, developed alongside Britain's GSK PLC, has produced successful results against the Omicron variant of the coronavirus in an efficacy study.

The French biopharmaceutical company said its vaccine candidate showed efficacy against the virus in an environment of high Omicron variation. It showed 72% efficacy against the strain in adult, as well as a favorable safety and tolerability profile, the company said.

Along with positive data from two previous trials, the results will be submitted to regulatory authorities for approval, Sanofi said.

The results "indicate the potential of Sanofi-GSK's next-generation Beta-based booster to be a relevant response to public health needs," the company said.

[netcurtains] 24/6/2022 16:43

not at 16:32 - I think we can all work that one out.

[jonjoneil] 24/6/2022 16:32

No chance :-)

[netcurtains] 24/6/2022 11:02

Relx up 3%

[pierre oreilly] 24/6/2022 10:57

Yes.

But impossible to know what the chance is or how you'd work it out!

[netcurtains] 24/6/2022 10:46

any chance this will break 1800 today?

[johnrxx99] 24/6/2022 10:29

I bow to your superior knowledge.

[tradermichael] 24/6/2022 10:08

Burroughs Wellcome became Wellcome became Glaxo Wellcome became GlaxoSmithKline became GSK.

Splitting off from Burroughs Wellcome became Wellcome Trust, the most philanthropic of all..

[maywillow] 24/6/2022 08:03

Sanofi SA said Friday that its coronavirus booster vaccine, developed alongside Britain's GSK PLC, has produced successful results against the Omicron variant of the coronavirus in an efficacy study.

The French biopharmaceutical company said its vaccine candidate showed efficacy against the virus in an environment of high Omicron variation. It showed 72% efficacy against the strain in adult, as well as a favorable safety and tolerability profile, the company said.

Along with positive data from two previous trials, the results will be submitted to regulatory authorities for approval, Sanofi said.

The results "indicate the potential of Sanofi-GSK's next-generation Beta-based booster to be a relevant response to public health needs," the company said.



Write to Joshua Kirby at [e-mail]; @joshualeokirby



(END) Dow Jones Newswires

June 24, 2022 02:06 ET (06:06 GMT)

[johnrxx99] 24/6/2022 05:10

Welcome also.

[gibbs1] 23/6/2022 16:26

Michele Maatouk
Sharecast News
23 Jun, 2022 15:21 23 Jun, 2022 15:26


GlaxoSmithKline to invest £1bn in infectious disease R&D


GlaxoSmithKline said on Thursday it will invest £1bn over ten years to accelerate research and development (R&D) into infectious diseases that disproportionately impact lower-income countries.



The research will focus on new and disruptive vaccines and medicines to prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases and anti-microbial resistance, which Glaxo said “continue to have a devastating toll on the most vulnerable, accounting for more than 60% of the disease burden in many lower-income countries".

Thomas Breuer, GSK’s chief global health officer, said: "I am delighted to renew our commitment to global health research for the coming decade, consistent with our purpose to unite our science, technology, and talent to get ahead of disease together and our ambition to deliver health impact at scale.

"Through our focus on scientific innovation in Global Health, we have delivered the first malaria vaccine, RTS,S, the first radical cure of vivax malaria, tafenoquine, and a new tuberculosis vaccine candidate."

He noted that the company now has more than 30 potential new vaccines and medicines - including pre-clinical assets - in 13 high-burden infectious diseases to accelerate.

[alphorn] 23/6/2022 14:21

Pfizer - eg. river blindness from memory.